Further, down-regulated expression of SP-D (and SP-A) at the malignant sites of human prostate adenocarcinomas as compared to the non-malignant sites and an association of weak SP-D (and SP-A) protein expression with an increasing Gleason score have been reported earlier (15). This evidence concerns the gene SFTPD and prostate adenocarcinoma.